| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011740155 |
| P356 | DOI | 10.1038/NATURE05282 |
| P3181 | OpenCitations bibliographic resource ID | 1904543 |
| P698 | PubMed publication ID | 17108972 |
| P5875 | ResearchGate publication ID | 6688812 |
| P50 | author | Claudio Bordignon | Q3679953 |
| Maurilio Sampaolesi | Q43375044 | ||
| Giuseppe D'Antona | Q46447827 | ||
| Beatriz G. Gálvez | Q52654733 | ||
| Yvan Torrente | Q56670654 | ||
| Sara Mantero | Q61853472 | ||
| Laura Perani | Q63677448 | ||
| P2093 | author name string | Anna Innocenzi | |
| Chiara Rinaldi | |||
| Giulio Cossu | |||
| Ines Barthélémy | |||
| Jean-Lauren Thibaud | |||
| M Gabriella Cusella De Angelis | |||
| Maria Guttinger | |||
| Nicolas Granger | |||
| Orietta Pansarasa | |||
| Paolo Mognol | |||
| Roberto Bottinelli | |||
| Rossana Tonlorenzi | |||
| Stephane Blot | |||
| P2860 | cites work | Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts | Q29302095 |
| Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells | Q33198739 | ||
| Clinical islet transplantation: advances and immunological challenges | Q35730793 | ||
| Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle | Q35835194 | ||
| New therapies for muscular dystrophy: cautious optimism | Q35908989 | ||
| Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration | Q36324366 | ||
| Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse | Q36403623 | ||
| Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability | Q39737560 | ||
| Skinned single fibers from normal and dystrophin-deficient dogs incur comparable stretch-induced force deficits | Q40442290 | ||
| Gene therapy research for Duchenne and Becker muscular dystrophies | Q41612646 | ||
| Visualizing the generation of memory CD4 T cells in the whole body | Q43695394 | ||
| Muscular dystrophy in a litter of golden retriever dogs | Q44032308 | ||
| Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. | Q44409495 | ||
| Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. | Q44434265 | ||
| Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy | Q45883916 | ||
| Bone marrow stromal cells generate muscle cells and repair muscle degeneration. | Q46588810 | ||
| Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. | Q52008649 | ||
| Mesoangioblasts, Vessel-Associated Multipotent Stem Cells, Repair the Infarcted Heart by Multiple Cellular Mechanisms | Q59120521 | ||
| An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy | Q59416437 | ||
| The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy | Q73755155 | ||
| The muscular dystrophies | Q77731754 | ||
| Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis | Q77963004 | ||
| Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs | Q80489703 | ||
| P2507 | corrigendum / erratum | Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. | Q43415956 |
| Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs | Q59070483 | ||
| P433 | issue | 7119 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 574-9 | |
| P577 | publication date | 2006-11-30 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs | |
| P478 | volume | 444 |
| Q33800712 | "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease |
| Q64969794 | (Epi)genetic Modifications in Myogenic Stem Cells: From Novel Insights to Therapeutic Perspectives. |
| Q50266029 | 14.1 T whole body MRI for detection of mesoangioblast stem cells in a murine model of Duchenne muscular dystrophy |
| Q42046048 | A Perspective on the Potential of Human iPS Cell-Based Therapies for Muscular Dystrophies: Advancements so far and Hurdles to Overcome |
| Q33523810 | A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping |
| Q24631410 | A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene |
| Q33571203 | A home away from home: challenges and opportunities in engineering in vitro muscle satellite cell niches |
| Q59099420 | A move in the right direction |
| Q30402365 | A new paradigm for the understanding of obesity: the role of stem cells |
| Q36151226 | A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy |
| Q54982478 | Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy. |
| Q42859445 | Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs |
| Q38169963 | Adiponectin as a tissue regenerating hormone: more than a metabolic function |
| Q64112448 | Adiponectin in Myopathies |
| Q37657502 | Adiponectin in health and diseases: from metabolic syndrome to tissue regeneration |
| Q26822437 | Advancements in stem cells treatment of skeletal muscle wasting |
| Q48110095 | Aging affects the in vivo regenerative potential of human mesoangioblasts. |
| Q39700737 | Airway tissue engineering |
| Q38237744 | Airway tissue engineering: an update |
| Q33713162 | Aldehyde dehydrogenase activity identifies a population of human skeletal muscle cells with high myogenic capacities |
| Q42840161 | Altered functional differentiation of mesoangioblasts in a genetic myopathy |
| Q55622381 | Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy. |
| Q30512264 | Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor |
| Q90255264 | An Overview about the Biology of Skeletal Muscle Satellite Cells |
| Q35154984 | An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration |
| Q39456951 | An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells |
| Q28084979 | Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy |
| Q38793354 | Anisotropic Materials for Skeletal-Muscle-Tissue Engineering. |
| Q39670600 | Applications of skeletal muscle progenitor cells for neuromuscular diseases |
| Q38747730 | Asynchronous inflammation and myogenic cell migration limit muscle tissue regeneration mediated by a cellular scaffolds |
| Q55361250 | At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients? |
| Q87954929 | Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts |
| Q40088153 | Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. |
| Q90285572 | Autologous transplantation of adipose-derived stem cells improves functional recovery of skeletal muscle without direct participation in new myofiber formation |
| Q28288148 | Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade |
| Q59876279 | Biomarkers of Duchenne muscular dystrophy: current findings |
| Q26863489 | Biomaterial-based delivery for skeletal muscle repair |
| Q33416809 | Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice |
| Q30552419 | Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement. |
| Q34069632 | Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice |
| Q42647177 | Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy |
| Q56689413 | Breaking the biological code |
| Q48554148 | Bystander effect on brain tissue of mesoangioblasts producing neurotrophins |
| Q37798837 | CD133(+) cells isolated from various sources and their role in future clinical perspectives |
| Q42520819 | CD90-positive cells, an additional cell population, produce laminin alpha2 upon transplantation to dy(3k)/dy(3k) mice. |
| Q37395711 | COUP-TFII regulates satellite cell function and muscular dystrophy |
| Q37358009 | CXCR4 enhances engraftment of muscle progenitor cells |
| Q83200918 | Cachexia and aging: an update based on the Fourth International Cachexia Meeting |
| Q90699692 | Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases |
| Q38176931 | Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man. |
| Q37548291 | Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies |
| Q44581360 | Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. |
| Q37639933 | Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics |
| Q58997812 | Cell Transplantation and “Stem Cell Therapy” in the Treatment of Myopathies: Many Promises in Mice, Few Realities in Humans |
| Q37581545 | Cell based therapy for Duchenne muscular dystrophy |
| Q35664379 | Cell therapy in muscular dystrophies: many promises in mice and dogs, few facts in patients |
| Q37624403 | Cell therapy strategies and improvements for muscular dystrophy. |
| Q38856714 | Cell-based secondary prevention of childbirth-induced pelvic floor trauma. |
| Q37944530 | Cell-matrix interactions in muscle disease |
| Q36119506 | Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation |
| Q37361381 | Cellular dynamics in the muscle satellite cell niche. |
| Q38136188 | Cellular kinetics of perivascular MSC precursors. |
| Q37701307 | Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass. |
| Q41887477 | Cellular players in skeletal muscle regeneration |
| Q38095518 | Cellular transitions and tissue engineering |
| Q38954041 | Characterization and Comparison of Canine Multipotent Stromal Cells Derived from Liver and Bone Marrow |
| Q33755416 | Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs |
| Q37610530 | Circulating Biomarkers for Duchenne Muscular Dystrophy. |
| Q34964840 | Coaxing stem cells for skeletal muscle repair |
| Q28547870 | Combinations of Kinase Inhibitors Protecting Myoblasts against Hypoxia |
| Q52564618 | Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. |
| Q37148808 | Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model |
| Q38267714 | Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions |
| Q39670210 | Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. |
| Q33847288 | Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice |
| Q59070483 | Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs |
| Q43415956 | Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. |
| Q37277411 | Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy |
| Q55283275 | Current Methods for Skeletal Muscle Tissue Repair and Regeneration. |
| Q37827157 | Current advances in cell therapy strategies for muscular dystrophies |
| Q34994545 | Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. |
| Q28082625 | Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy |
| Q39641618 | DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy |
| Q27309883 | Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell Transplantation |
| Q45883783 | Discrepancies between the fate of myoblast xenograft in mouse leg muscle and NMR label persistency after loading with Gd-DTPA or SPIOs |
| Q92621566 | Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? |
| Q42175045 | Duchenne muscular dystrophy gene therapy in the canine model |
| Q35641673 | Duchenne muscular dystrophy gene therapy in the canine model. |
| Q89782554 | Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies |
| Q33608478 | Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies |
| Q58716650 | Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine |
| Q33730444 | Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. |
| Q37111368 | Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. |
| Q21245473 | Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic? |
| Q21560888 | Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle |
| Q34489678 | Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy |
| Q34205540 | Efficient in vitro myogenic reprogramming of human primary mesenchymal stem cells and endothelial cells by Myf5. |
| Q37783366 | Embryo biotechnology in the dog: a review |
| Q41390937 | Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle |
| Q36363716 | Emerging drugs for Duchenne muscular dystrophy |
| Q38209315 | Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells |
| Q38808814 | Emerging new tools to study and treat muscle pathologies: genetics and molecular mechanisms underlying skeletal muscle development, regeneration, and disease |
| Q36960845 | Emerging strategies for cell and gene therapy of the muscular dystrophies |
| Q35435528 | Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice. |
| Q42592508 | Endothelial Network Formation Within Human Tissue-Engineered Skeletal Muscle |
| Q38878001 | Endothelial sphingosine kinase/SPNS2 axis is critical for vessel-like formation by human mesoangioblasts. |
| Q39076292 | Engineering skeletal muscle - from two to three dimensions. |
| Q36670780 | Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy |
| Q37386340 | Engraftment of embryonic stem cell-derived myogenic progenitors in a dominant model of muscular dystrophy |
| Q33713683 | Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. |
| Q38112733 | Epigenetic control of skeletal muscle regeneration: Integrating genetic determinants and environmental changes |
| Q36480691 | Equine-Induced Pluripotent Stem Cells Retain Lineage Commitment Toward Myogenic and Chondrogenic Fates |
| Q47115483 | Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. |
| Q52680178 | Evolutionary conservation in myoblast fusion. |
| Q34508301 | Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease |
| Q33931564 | Expression of dog microdystrophin in mouse and dog muscles by gene therapy |
| Q38129288 | Fate choice of post-natal mesoderm progenitors: skeletal versus cardiac muscle plasticity |
| Q57248351 | Fate of mesoangioblasts in a vaginal birth injury model: influence of the route of administration |
| Q38249175 | Fetal stem cells and skeletal muscle regeneration: a therapeutic approach |
| Q37232240 | Finding a better drug for epilepsy: antiepileptogenesis targets. |
| Q53083043 | First study of intra-arterial delivery of myogenic mononuclear cells to skeletal muscles in primates. |
| Q33298810 | Fluorescence detection of protein clusters in individual cells and tissue sections by using toponome imaging system: sample preparation and measuring procedures |
| Q30478686 | Following damage, the majority of bone marrow-derived airway cells express an epithelial marker |
| Q35735727 | Functional myogenic engraftment from mouse iPS cells. |
| Q51966818 | Functional skeletal muscle regeneration from differentiating embryonic stem cells. |
| Q33455443 | Functional substitution by TAT-utrophin in dystrophin-deficient mice |
| Q33555880 | Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis |
| Q34180144 | Gene Therapy for Muscular Dystrophies: Progress and Challenges |
| Q33831193 | Gene and cell-mediated therapies for muscular dystrophy. |
| Q37171838 | Gene doping: the hype and the reality. |
| Q37519650 | Gene therapy for muscular dystrophy: current progress and future prospects. |
| Q35095260 | Gene therapy for the inner ear: challenges and promises |
| Q37396408 | Gene therapy in large animal models of muscular dystrophy |
| Q39913570 | Gene transfer using HACs: a key step closer to ex vivo gene therapy using autologous gene-corrected cells to treat muscular dystrophy |
| Q83023116 | Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells |
| Q39570584 | Globular adiponectin as a complete mesoangioblast regulator: role in proliferation, survival, motility, and skeletal muscle differentiation. |
| Q64063237 | Growth Factor Screening in Dystrophic Muscles Reveals PDGFB/PDGFRB-Mediated Migration of Interstitial Stem Cells |
| Q92173189 | Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify for autologous therapy |
| Q38272315 | Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. |
| Q39516901 | Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin |
| Q35238272 | Human artificial chromosomes for gene delivery and the development of animal models |
| Q46003427 | Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. |
| Q34636219 | Human first-trimester chorionic villi have a myogenic potential |
| Q37671010 | Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways. |
| Q64069475 | Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies |
| Q50657951 | Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro. |
| Q39840459 | Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. |
| Q35180169 | Human myogenic endothelial cells exhibit chondrogenic and osteogenic potentials at the clonal level. |
| Q52714547 | Human serum and platelet lysate are appropriate xeno-free alternatives for clinical-grade production of human MuStem cell batches. |
| Q33562298 | Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice |
| Q48223753 | Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies |
| Q36329380 | Identification of a novel microRNA that regulates the proliferation and differentiation in muscle side population cells |
| Q41998193 | Immunological properties of embryonic and adult stem cells |
| Q37042189 | Impaired regeneration: A role for the muscle microenvironment in cancer cachexia |
| Q54401551 | In Vitro Adult Canine Adipose Tissue-Derived Stromal Cell Growth Characteristics |
| Q39502175 | In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study |
| Q96817083 | In vivo stem cell tracking using scintigraphy in a canine model of DMD |
| Q26753150 | Increased Understanding of Stem Cell Behavior in Neurodegenerative and Neuromuscular Disorders by Use of Noninvasive Cell Imaging |
| Q36082158 | Increased survival of muscle stem cells lacking the MyoD gene after transplantation into regenerating skeletal muscle |
| Q34249466 | Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy |
| Q28389778 | Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q42611487 | Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways |
| Q33736192 | Influence of immune responses in gene/stem cell therapies for muscular dystrophies |
| Q37280594 | Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease |
| Q22001191 | Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration. |
| Q36861720 | Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy. |
| Q27317882 | Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance |
| Q36410147 | Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy |
| Q33785188 | Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data |
| Q36933565 | Intrinsic ability of adult stem cell in skeletal muscle: an effective and replenishable resource to the establishment of pluripotent stem cells |
| Q46093325 | Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs |
| Q38269131 | Invited review: Stem cells and muscle diseases: advances in cell therapy strategies |
| Q52899792 | Isolation and Characterization of Vessel-Associated Stem/Progenitor Cells from Skeletal Muscle. |
| Q50642774 | Isolation and characterization of mesenchymal progenitors derived from the bone marrow of goats native from northeastern Brazil. |
| Q48392304 | Isolation, characterization, and differentiation potential of canine adipose-derived stem cells |
| Q42323278 | Laminin differentially regulates the stemness of type I and type II pericytes |
| Q27318580 | Laminin regulates PDGFRβ(+) cell stemness and muscle development. |
| Q37246026 | Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy |
| Q35665202 | Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy |
| Q38823382 | Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy. |
| Q33871731 | Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs |
| Q34093219 | MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers |
| Q39901699 | Macrophage-secreted factors enhance the in vitro expansion of DMD muscle precursor cells while preserving their myogenic potential |
| Q38008341 | Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration |
| Q33369840 | Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis |
| Q35671985 | Magnetic Resonance Assessment of Hypertrophic and Pseudo-Hypertrophic Changes in Lower Leg Muscles of Boys with Duchenne Muscular Dystrophy and Their Relationship to Functional Measurements |
| Q34973330 | Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice |
| Q26824418 | Meat Science and Muscle Biology Symposium: stem cell niche and postnatal muscle growth |
| Q34110253 | Meganucleases can restore the reading frame of a mutated dystrophin |
| Q27320302 | Membrane Blebbing Is Required for Mesenchymal Precursor Migration |
| Q51761478 | Mesenchymal Stem Cells in the Musculoskeletal System: From Animal Models to Human Tissue Regeneration? |
| Q37560090 | Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy |
| Q36027867 | Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A. |
| Q37917718 | Mesoangioblasts of inclusion-body myositis: a twofold tool to study pathogenic mechanisms and enhance defective muscle regeneration |
| Q41913552 | Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways |
| Q27331430 | Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle |
| Q34541781 | Method for obtaining committed adult mesenchymal precursors from skin and lung tissue |
| Q36740284 | Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy |
| Q24568176 | Molecular and cell-based therapies for muscle degenerations: a road under construction |
| Q51748228 | Morphological and functional analyses of skeletal muscles from an immunodeficient animal model of limb girdle muscular dystrophy type 2E. |
| Q37359967 | Multiplicity of experimental approaches to therapy for genetic muscle diseases and necessity for population screening |
| Q42512827 | Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy |
| Q79849762 | Mural cells paint a new picture of muscle stem cells |
| Q36855778 | Muscle CD31(-) CD45(-) side population cells promote muscle regeneration by stimulating proliferation and migration of myoblasts. |
| Q39155795 | Muscle Interstitial Cells: A Brief Field Guide to Non-satellite Cell Populations in Skeletal Muscle |
| Q26752770 | Muscle Satellite Cells: Exploring the Basic Biology to Rule Them |
| Q51838662 | Muscle Stem Cells: A Model System for Adult Stem Cell Biology. |
| Q41136552 | Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. |
| Q26742069 | Muscle injuries and strategies for improving their repair |
| Q42118907 | Muscle satellite cells and endothelial cells: close neighbors and privileged partners |
| Q36975851 | Muscle stem cells and model systems for their investigation |
| Q34171695 | Muscular dystrophy, incurability, eugenics. |
| Q37792883 | Myoblast transplantation: A possible surgical treatment for a severe pediatric disease |
| Q38014316 | Myogenesis and muscle regeneration |
| Q26799633 | Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
| Q47286671 | Myogenic progenitor specification from pluripotent stem cells. |
| Q36444539 | Myogenic reprogramming of retina-derived cells following their spontaneous fusion with myotubes |
| Q42031266 | Necdin enhances muscle reconstitution of dystrophic muscle by vessel-associated progenitors, by promoting cell survival and myogenic differentiation |
| Q37217303 | Neuromuscular disorders: genes, genetic counseling and therapeutic trials |
| Q36168025 | Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors |
| Q36043923 | Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. |
| Q37716791 | Non-myogenic Contribution to Muscle Development and Homeostasis: The Role of Connective Tissues |
| Q37786521 | Novel therapeutic approaches for inclusion body myositis. |
| Q28072269 | Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture |
| Q48314148 | Oxidative stress preconditioning of mouse perivascular myogenic progenitors selects a subpopulation of cells with a distinct survival advantage in vitro and in vivo. |
| Q35197078 | PW1/Peg3 expression regulates key properties that determine mesoangioblast stem cell competence |
| Q33833512 | Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. |
| Q92421314 | Pericytes in Muscular Dystrophies |
| Q46899831 | Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells |
| Q34201678 | Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle |
| Q27013613 | Perspectives of stem cell therapy in Duchenne muscular dystrophy |
| Q34152280 | Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials |
| Q33809437 | Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy |
| Q30457905 | Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods |
| Q42663428 | PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle |
| Q28088720 | Plasticity of spermatogonial stem cells |
| Q50076158 | Plasticity of the Muscle Stem Cell Microenvironment |
| Q33525796 | Porous poly (L-lactic acid) scaffolds are optimal substrates for internal colonization by A6 mesoangioblasts and immunocytochemical analyses. |
| Q90080159 | Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies |
| Q26798810 | Potential of adipose-derived stem cells in muscular regenerative therapies |
| Q45873802 | Preclinical and clinical advances in transposon-based gene therapy |
| Q35113901 | Preclinical studies with umbilical cord mesenchymal stromal cells in different animal models for muscular dystrophy |
| Q56564487 | Prenatal gene therapy for the early treatment of genetic disorders |
| Q35627456 | Prevention of muscle aging by myofiber-associated satellite cell transplantation |
| Q37908904 | Progress in therapy for Duchenne muscular dystrophy. |
| Q80982228 | Prospective identification of myogenic endothelial cells in human skeletal muscle |
| Q50505656 | Protective effect of sodium ascorbate on efficacy of intramuscular transplantation of autologous muscle-derived cells. |
| Q38391853 | Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells. |
| Q92489474 | Recent advances in Duchenne muscular dystrophy |
| Q26741409 | Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials |
| Q37678176 | Recent advances in lentiviral vector development and applications |
| Q27014183 | Recent progress in satellite cell/myoblast engraftment -- relevance for therapy |
| Q30545559 | Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy |
| Q37274303 | Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy |
| Q50430044 | Regulation and phylogeny of skeletal muscle regeneration |
| Q33841066 | Regulatory interactions between muscle and the immune system during muscle regeneration |
| Q35549208 | Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy |
| Q38079633 | Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies |
| Q33559684 | Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells |
| Q42954387 | Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. |
| Q64228902 | Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches |
| Q26778322 | Role of Inflammation in Muscle Homeostasis and Myogenesis |
| Q38023085 | S1P lyase in skeletal muscle regeneration and satellite cell activation: exposing the hidden lyase |
| Q60067425 | Sampaolesi et al. reply |
| Q35758335 | Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects |
| Q33702390 | Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy |
| Q57597830 | Satellite cells, the engines of muscle repair |
| Q35212612 | Sculpting chromatin beyond the double helix: epigenetic control of skeletal myogenesis. |
| Q41137706 | Sdf-1 (CXCL12) induces CD9 expression in stem cells engaged in muscle regeneration. |
| Q42322388 | Semitendinosus myopathy and treatment with adipose-derived stem cells in working German shepherd police dogs |
| Q46190014 | Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model |
| Q46245053 | Skeletal Muscle Regenerative Potential of Human MuStem Cells following Transplantation into Injured Mice Muscle. |
| Q37422514 | Skeletal muscle as a paradigm for regenerative biology and medicine |
| Q37719612 | Skeletal muscle fibre diversity and the underlying mechanisms. |
| Q33854768 | Skeletal muscle generated from induced pluripotent stem cells - induction and application |
| Q53356030 | Skeletal muscle perfusion and stem cell delivery in muscle disorders using intra-femoral artery canulation in mice. |
| Q33533313 | Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice |
| Q36998129 | Skeletal muscle satellite cells and adult myogenesis. |
| Q34322871 | Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications |
| Q36455338 | Smad1/5/8 are myogenic regulators of murine and human mesoangioblasts |
| Q38815247 | Sodium Iodide Symporter PET and BLI Noninvasively Reveal Mesoangioblast Survival in Dystrophic Mice |
| Q42159938 | Sources for skeletal muscle repair: from satellite cells to reprogramming |
| Q38170107 | Sphingosine 1-phosphate axis: a new leader actor in skeletal muscle biology. |
| Q40033034 | Spontaneous myogenic differentiation of Flk-1-positive cells from adult pancreas and other nonmuscle tissues. |
| Q38577279 | Stem Cell Differentiation Toward the Myogenic Lineage for Muscle Tissue Regeneration: A Focus on Muscular Dystrophy |
| Q36771273 | Stem and progenitor cells in skeletal muscle development, maintenance, and therapy |
| Q35237141 | Stem cell approaches in psychiatry--challenges and opportunities. |
| Q37754873 | Stem cell therapy for cystic fibrosis: current status and future prospects |
| Q99568694 | Stem cell therapy for muscular dystrophies |
| Q35087066 | Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease |
| Q37458386 | Stem cell through present and future |
| Q33902416 | Stem cell transplantation for muscular dystrophy: the challenge of immune response |
| Q34997665 | Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysis |
| Q60067428 | Stem cell treatment of dystrophic dogs |
| Q36825858 | Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases |
| Q26828390 | Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks |
| Q35088530 | Stem cells for skeletal muscle repair |
| Q35849847 | Stem cells in dental pulp of deciduous teeth. |
| Q37807624 | Stem cells to treat muscular dystrophies – Where are we? |
| Q33713999 | Strategies to modulate immune responses: a new frontier for gene therapy |
| Q39258476 | Strength and muscle specificity of a compact promoter derived from the slow troponin I gene in the context of episomal (gutless adenovirus) and integrating (lentiviral) vectors |
| Q38857890 | Striated muscle function, regeneration, and repair |
| Q51328073 | Suppression of Canine Dendritic Cell Activation/Maturation and Inflammatory Cytokine Release by Mesenchymal Stem Cells Occurs Through Multiple Distinct Biochemical Pathways. |
| Q35124906 | Syndecan-4-expressing muscle progenitor cells in the SP engraft as satellite cells during muscle regeneration. |
| Q35475301 | Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs |
| Q37591115 | Targeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles. |
| Q92874029 | The Dog Model in the Spotlight: Legacy of a Trustful Cooperation |
| Q58719281 | The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models |
| Q64068253 | The effect of type 2 diabetes mellitus and obesity on muscle progenitor cell function |
| Q36676324 | The emerging biology of muscle stem cells: implications for cell-based therapies. |
| Q37219522 | The genetics of vertebrate myogenesis |
| Q33709114 | The golden retriever model of Duchenne muscular dystrophy |
| Q47322422 | The increase of pericyte population in human neuromuscular disorders supports their role in muscle regeneration in vivo |
| Q28656377 | The mdx mouse model as a surrogate for Duchenne muscular dystrophy |
| Q37978773 | The origin and fate of muscle satellite cells. |
| Q37585530 | The origin, molecular regulation and therapeutic potential of myogenic stem cell populations |
| Q37325686 | The potential of stem cells in the treatment of cardiovascular diseases |
| Q45166575 | The role of immunosuppression in gene- and cell-based treatments for duchenne muscular dystrophy |
| Q37209658 | The therapeutic potential of embryonic and adult stem cells for skeletal muscle regeneration |
| Q37383091 | The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies |
| Q38014348 | The vascular stem cell niche. |
| Q37455625 | Therapeutic advances in muscular dystrophy |
| Q34982869 | Therapeutic approaches to muscular dystrophy. |
| Q38264461 | Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy |
| Q36883572 | Tissue engineering for skeletal muscle regeneration |
| Q36861771 | Tissue-Specific Cultured Human Pericytes: Perivascular Cells from Smooth Muscle Tissue Have Restricted Mesodermal Differentiation Ability |
| Q38114163 | Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: collaborators or saboteurs? |
| Q37157871 | Toponomics and neurotoponomics: a new way to medical systems biology |
| Q30486685 | Transcriptional and functional differences in stem cell populations isolated from extraocular and limb muscles |
| Q59876164 | Transduction of Full-length Dystrophin to Multiple Skeletal Muscles Improves Motor Performance and Life Span in Utrophin/Dystrophin Double Knockout Mice |
| Q59001351 | Translational Research in Stem Cell Treatment of Neuromuscular Diseases |
| Q30542052 | Transplantated mesenchymal stem cells derived from embryonic stem cells promote muscle regeneration and accelerate functional recovery of injured skeletal muscle |
| Q53097033 | Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs is a Safe Procedure. |
| Q42819955 | Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. |
| Q39261708 | Transplantation of induced pluripotent stem cell-derived mesoangioblast-like myogenic progenitors in mouse models of muscle regeneration |
| Q92846144 | Transplantation studies reveal internuclear transfer of toxic RNA in engrafted muscles of myotonic dystrophy 1 mice |
| Q46707720 | Treatment options for Duchenne muscular dystrophy |
| Q36021334 | Understanding hereditary diseases using the dog and human as companion model systems |
| Q38074834 | Update on the treatment of Duchenne muscular dystrophy |
| Q33586182 | Use of Lentiviral Particles As a Cell Membrane-Based mFasL Delivery System for In Vivo Treatment of Inflammatory Arthritis. |
| Q28469278 | Utrophin up-regulation by an artificial transcription factor in transgenic mice |
| Q27307745 | Validity of a Neurological Scoring System for Canine X-Linked Myotubular Myopathy |
| Q51631666 | Validity of a neurological scoring system for canine X-linked myotubular myopathy. |
| Q88998647 | Vascular Delivery of Allogeneic MuStem Cells in Dystrophic Dogs Requires Only Short-Term Immunosuppression to Avoid Host Immunity and Generate Clinical/Tissue Benefits |
| Q41844106 | Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS. |
| Q36055604 | Vascular smooth muscle progenitor cells: building and repairing blood vessels. |
| Q34992272 | Vessel-associated stem cells from skeletal muscle: From biology to future uses in cell therapy |
| Q61806874 | iPSCs as a Platform for Disease Modeling, Drug Screening, and Personalized Therapy in Muscular Dystrophies |
| Q28592363 | miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors |
| Q37379324 | miRNAS in normal and diseased skeletal muscle |
| Q36532676 | piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts |
| Q36119288 | uPA deficiency exacerbates muscular dystrophy in MDX mice |
Search more.